101.49
-1.26 (-1.23%)
| Previous Close | 102.75 |
| Open | 102.75 |
| Volume | 792,139 |
| Avg. Volume (3M) | 1,942,007 |
| Market Cap | 15,792,674,816 |
| Price / Earnings (TTM) | 12.85 |
| Price / Earnings (Forward) | 20.28 |
| Price / Sales | 3.67 |
| Price / Book | 6.76 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -22.27% |
| Operating Margin (TTM) | 17.67% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | -3.30% |
| Total Debt/Equity (MRQ) | 110.09% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | 1.00 B |
| Levered Free Cash Flow (TTM) | 381.00 M |
| Return on Assets (TTM) | 4.96% |
| Return on Equity (TTM) | -23.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Illumina, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.0 |
| Average | -1.50 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 101.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Guardcap Asset Management Ltd | 30 Jun 2025 | 2,037,437 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 132.00 (Evercore ISI Group, 30.06%) | Buy |
| Median | 105.00 (3.46%) | |
| Low | 95.00 (Barclays, -6.40%) | Sell |
| Average | 111.33 (9.70%) | |
| Total | 2 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 98.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 132.00 (30.06%) | Buy | 96.68 |
| Barclays | 02 Oct 2025 | 95.00 (-6.39%) | Sell | 99.30 |
| 01 Aug 2025 | 90.00 (-11.32%) | Sell | 94.66 | |
| Morgan Stanley | 04 Aug 2025 | 105.00 (3.46%) | Hold | 98.44 |
| Canaccord Genuity | 01 Aug 2025 | 105.00 (3.46%) | Hold | 94.66 |
| RBC Capital | 01 Aug 2025 | 126.00 (24.15%) | Buy | 94.66 |
| Baird | 28 Jul 2025 | 105.00 (3.46%) | Hold | 109.88 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| THAYSEN JACOB | - | 102.12 | -1,301 | -132,858 |
| ULLEM SCOTT B. | 94.97 | - | 252 | 23,932 |
| Aggregate Net Quantity | -1,049 | |||
| Aggregate Net Value ($) | -108,926 | |||
| Aggregate Avg. Buy ($) | 94.97 | |||
| Aggregate Avg. Sell ($) | 102.12 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| THAYSEN JACOB | Officer | 05 Oct 2025 | Disposed (-) | 1,301 | 102.12 | 132,858 |
| ULLEM SCOTT B. | Director | 30 Sep 2025 | Acquired (+) | 252 | 94.97 | 23,932 |
| Date | Type | Details |
|---|---|---|
| 01 Oct 2025 | Announcement | Illumina launches new business to accelerate technology and data-driven discovery |
| 23 Sep 2025 | Announcement | Illumina advances personalized cancer care with new pharma development partnerships |
| 18 Sep 2025 | Announcement | Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine |
| 03 Sep 2025 | Announcement | Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development |
| 31 Jul 2025 | Announcement | Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 |
| 30 Jul 2025 | Announcement | Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |